Rani Therapeutics Holdings, Inc. Class A Share Price
RANIRani Therapeutics Holdings, Inc. Class A Stock Performance
Open $0.82 | Prev. Close $0.76 | Circuit Range N/A |
Day Range $0.81 - $0.85 | Year Range $0.39 - $3.85 | Volume 22,097 |
Average Traded $0.83 |
Rani Therapeutics Holdings, Inc. Class A Share Price Chart
About Rani Therapeutics Holdings, Inc. Class A
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Rani Therapeutics Holdings, Inc. Class A Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
13-Apr-26 | $0.72 | $0.76 | +2.98% |
10-Apr-26 | $0.77 | $0.74 | -4.40% |
09-Apr-26 | $0.83 | $0.77 | -6.98% |
08-Apr-26 | $0.86 | $0.83 | +2.34% |
07-Apr-26 | $0.80 | $0.81 | -1.93% |
06-Apr-26 | $0.84 | $0.83 | -0.84% |
02-Apr-26 | $0.78 | $0.83 | +3.86% |